Background and study aim: Alphafetoprotein (AFP) cannot be relied on alone for diagnosis of hepatocellular carcinoma (HCC). However, it may have a prognostic value and can be used for monitoring response to different modalities of treatment for HCC. This study aimed to differentiate the clinical and pathological features of HCCs according to AFP levels.
Subjects
and Methods: This retrospective study included 60 patients with HCC secondary to chronic hepatitis C (HCV). They were divided based on serum AFP into two groups; group I; included 30 patients with AFP lower than 302.5ng/ml. and group II; included 30 patients with AFP higher than 302.5ng/ml. clinical, laboratory and pathological differences between both groups were compared.
INTRODUCTION
Hepatocellular carcinoma (HCC) is among the most common malignant tumors in the world [1]. In Egypt, the incidence of HCC has been doubling over a decade and ranks the 2nd and 6th most common cancers among males and females, respectively [2] . This is attributed to high burden of chronic hepatitis C virus (HCV) infection. It has been reported as the highest prevalence worldwide Also, such issues are needed to be compared among patients with different AFP levels. This study aimed to evaluate the clinical, laboratory and pathological differences of HCC, secondary to chronic hepatitis C, based on their capability in secreting AFP.
PATIENTS AND METHODS

Patients' selection:
This is a retrospective study that analyzed 60 patients diagnosed to have HCC secondary to chronic HCV. After treatment of chronic HCV using direct-acting antiviral therapy (DAA), patients were underwent different treatment modalities for HCC; radiofrequency ablation (RFA), microwave, local alcohol injection and trans-arterial chemoembolization (TACE) at the tropical department, zagazig university hospitals, during the period between January 2017 and December 2018. Diagnosis of HCC was based on the results of dynamic imaging (triple phase computed tomography or magnetic resonance imaging). Since, this study was a retrospective one, the diagnosis of HCC was confirmed in all patients. Because of high AFP levels observed among this cohort of Patients before treatment of HCC, they were divided into two groups based on the median level of AFP among all patients.
Group I; included 30 patients with AFP levels (<302.5ng/ml) Group II; included 30 patients with AFP levels (>302.5ng/ml)
The clinical, laboratory and pathological characteristics were reviewed between these 2 groups .
For each patient the following data were collected; The recurrence of HCC was seen in 11(18.3%) patients out of 60 analyzed patients. Although patients with higher AFP secreting tumors showed higher rate of HCC recurrence in comparison to those with lower AFP secreting tumors (8 patients vs. 3 patients, P value; 0.181), this was non-significant difference. To evaluate the relationship between AFP levels and the rate of HCC recurrence after locoregional therapy, we performed logistic regression and showed that odds ratio was 1 (confidence interval 0.99-1.00, p value 04), which was non-significant difference between both groups. This study also evaluated the accuracy of the high AFP in prediction of HCC recurrence, based on the cutoff value of the median (302.5ng/mL), values higher than 302.5ng/mL had higher sensitivity, specificity and positive predictive value compared to those with lower AFP values. From this study, it is apparent that high HCV viraemia was correlated with the occurrence of HCC, which is consistent with that reported by Ran Noh et al; 2016 who revealed that HCV viral load is considered risk factor for the development of HCC [15] . Also, in this study high HCV viraemia was associated with higher AFP-secreting HCC. In our cohort of patients, the underlying cause of HCC was cirrhosis secondary to chronic hepatitis C (HCV). However, although the prevalence of occult HBV infection among the patients was not significantly different but it seems higher in the group of the patients with higher AFP secreting HCC, this was consistent with that found in Gurakar et al; 2018 who found that chronic hepatitis B virus (HBV) was more common among patients with higher AFP levels compared to those with low AFP-secreting tumors (16.4% vs. 4.8%, p=0.068) [13].
CONCLUSION
Hepatocellular carcinoma-secreting high levels of AFP are larger and aggressive in their behaviour when compared to HCC with low AFP-secretion.
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